Riverbridge Partners LLC Reduces Stock Position in OrthoPediatrics Corp. $KIDS

Riverbridge Partners LLC lessened its position in shares of OrthoPediatrics Corp. (NASDAQ:KIDS) by 13.8% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 321,040 shares of the company’s stock after selling 51,438 shares during the quarter. Riverbridge Partners LLC’s holdings in OrthoPediatrics were worth $6,896,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the company. Harbor Capital Advisors Inc. grew its stake in OrthoPediatrics by 116.5% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 333,959 shares of the company’s stock valued at $7,173,000 after purchasing an additional 179,733 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in OrthoPediatrics by 112.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 200,439 shares of the company’s stock valued at $4,937,000 after purchasing an additional 106,041 shares during the last quarter. Jane Street Group LLC purchased a new stake in OrthoPediatrics during the 1st quarter valued at about $389,000. Millennium Management LLC grew its stake in OrthoPediatrics by 55.3% during the 1st quarter. Millennium Management LLC now owns 656,578 shares of the company’s stock valued at $16,172,000 after purchasing an additional 233,873 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in OrthoPediatrics by 6.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock valued at $246,000 after purchasing an additional 645 shares during the last quarter. Hedge funds and other institutional investors own 69.05% of the company’s stock.

Analyst Upgrades and Downgrades

KIDS has been the topic of several research analyst reports. Wall Street Zen upgraded OrthoPediatrics from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th. Citigroup reissued a “market outperform” rating on shares of OrthoPediatrics in a report on Friday, August 8th. JMP Securities set a $35.00 price objective on OrthoPediatrics and gave the company a “market outperform” rating in a report on Friday, August 8th. Finally, BTIG Research decreased their price objective on OrthoPediatrics from $40.00 to $39.00 and set a “buy” rating for the company in a report on Wednesday, August 6th. Seven research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $34.14.

Insiders Place Their Bets

In other OrthoPediatrics news, CFO Fred Hite purchased 5,076 shares of OrthoPediatrics stock in a transaction that occurred on Thursday, August 21st. The stock was bought at an average price of $19.41 per share, with a total value of $98,525.16. Following the acquisition, the chief financial officer owned 213,065 shares of the company’s stock, valued at $4,135,591.65. This trade represents a 2.44% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 32.70% of the company’s stock.

OrthoPediatrics Stock Performance

NASDAQ KIDS opened at $18.89 on Thursday. The stock has a market capitalization of $473.65 million, a price-to-earnings ratio of -10.55 and a beta of 1.06. OrthoPediatrics Corp. has a twelve month low of $16.59 and a twelve month high of $32.00. The company has a current ratio of 6.66, a quick ratio of 3.43 and a debt-to-equity ratio of 0.27. The stock has a 50-day moving average of $20.47 and a 200 day moving average of $21.63.

OrthoPediatrics (NASDAQ:KIDS) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.06. The company had revenue of $61.08 million during the quarter, compared to analysts’ expectations of $61.40 million. OrthoPediatrics had a negative return on equity of 6.36% and a negative net margin of 18.92%. OrthoPediatrics has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that OrthoPediatrics Corp. will post -0.93 EPS for the current fiscal year.

OrthoPediatrics Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.